U.K’s NICE recommends NanoString’s Prosigna Assay for chemotherapy in breast cancer patients

|About: NanoString Technologies (NSTG)|By:, SA News Editor

NanoString Technologies (NASDAQ:NSTG) announces that health officials from the National Institute for Health and Care Excellence (NICE) in U.K. recommends use of the Prosigna Breast Cancer Gene Signature Assay result to guide adjuvant chemotherapy decisions for early-stage breast cancer patients.

Subscribe for full text news in your inbox